


5

CLAIMS

What is claimed is:

1. A compound comprising



or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2


15 carbon atoms may be substituted with S or O;

Z is O, S, or NR;

X is selected from the group consisting of CO_2H , $CONHR_2$, $CONR_2$,

$CON(OR)R$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH , $P(O)(OH)_2$,

$CONHSO_2R$, SO_2NR_2 , SO_2NHR , and



20

;


J is $C=O$ or $CHOH$;

R is independently H, C_1-C_6 alkyl, phenyl, or biphenyl; and

E is C_3-C_6 alkyl, C_4-C_{10} cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.


25

2. The compound of claim 1 comprising



5 or a pharmaceutically acceptable salt or a prodrug thereof.

3. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

4. The compound of claim 3 wherein Z is O.

10 5. The compound of claim 3 wherein Z is S.

6. The compound of claim 3 wherein Z is NH.

7. The compound of claim 3 wherein J is C=O.


8. The compound of claim 3 wherein J is CHOH.

9. The compound of claim 3 wherein X is CO₂H.

15 10. The compound of claim 3 wherein E is phenyl, thienyl, furyl, pyridinyl, naphthyl, benzothienyl, or benzofuryl having from 0 to 2 substituents comprising up to 4 non-hydrogen atoms.


11. The compound of claim 3 wherein E is *n*-butyl.

12. The compound of claim 1 comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

13. The compound of claim 1 comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

14. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

10 15. A liquid composition comprising



or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

15 A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2 carbon atoms may be substituted with S or O;


Z is O, S, or NR;

X is selected from the group consisting of CO_2H , $CONHR_2$, $CONR_2$,

$CON(OR)R$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH , $P(O)(OH)_2$,

20 $CONHSO_2R$, SO_2NR_2 , SO_2NHR , and

5




; J is C=O or CHOH;

R is independently H, C₁-C₆ alkyl, phenyl, or biphenyl; and

- E is C₃-C₆ alkyl, C₄-C₁₀ cycloalkyl, phenyl or napthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein
10 said substituents comprise up to 4 non-hydrogen atoms;
wherein said liquid is formulated for ophthalmic use.

16. A method comprising administering a compound to a mammal, wherein said method is useful for the treatment of glaucoma or ocular hypertension in said mammal, said compound comprising

15



or a pharmaceutically acceptable salt or a prodrug thereof;


wherein a dashed line represents the presence or absence of a double bond or a triple bond;

- A is -(CH₂)₆-, cis -CH₂CH=CH-(CH₂)₃-, or -CH₂C≡C-(CH₂)₃-, wherein 1 or 2
20 carbon atoms may be substituted with S or O;

Z is O, S, or NR;

X is selected from the group consisting of CO₂H, CONHR₂, CONR₂, CON(OR)R, CON(CH₂CH₂OH)₂, CONH(CH₂CH₂OH), CH₂OH, P(O)(OH)₂, CONHSO₂R, SO₂NR₂, SO₂NHR, and

25



; J is C=O or CHOH;

R is independently H, C₁-C₆ alkyl, phenyl, or biphenyl; and

- 5 E is C₃-C₆ alkyl, C₄-C₁₀ cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.